Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection

BACKGROUND: HCV direct-acting antivirals (DAAs) are produced in India at low cost. However, concerns surrounding reinfection and budgetary impact limit treatment scale-up in India. We evaluate the cost-effectiveness and budgetary impact of HCV treatment in India, including reinfection. METHODS: A cl...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:PLoS One
Autors principals: Chaillon, Antoine, Mehta, Sanjay R., Hoenigl, Martin, Solomon, Sunil S., Vickerman, Peter, Hickman, Matthew, Skaathun, Britt, Martin, Natasha K.
Format: Artigo
Idioma:Inglês
Publicat: Public Library of Science 2019
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6553784/
https://ncbi.nlm.nih.gov/pubmed/31170246
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0217964
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars